About Sonoma Pharmaceuticals (NASDAQ:SNOA)
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. Its products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis. The company's Microcyn medical devices are used for cleaning, debridement, lubricating, moistening, and dressing of acute and chronic wounds in tissue care management. It also operates a microbiology contract testing laboratory that offers consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Sonoma Pharmaceuticals, Inc. sells its products directly to end users, as well as to distributors; and through in-house sales force and call center to hospitals, physicians, nurses, and other healthcare practitioners. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-0.92
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$16.66 million
Price / Sales0.83
Price / CashN/A
Book Value$5.00 per share
Price / Book0.58
EPS (Most Recent Fiscal Year)($3.16)
Return on Equity-87.71%
Return on Assets-70.56%
Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions
What is Sonoma Pharmaceuticals' stock symbol?
Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."
How were Sonoma Pharmaceuticals' earnings last quarter?
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) announced its earnings results on Wednesday, June, 13th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.34. The company had revenue of $3.66 million for the quarter, compared to analyst estimates of $4.51 million. Sonoma Pharmaceuticals had a negative return on equity of 87.71% and a negative net margin of 86.01%. View Sonoma Pharmaceuticals' Earnings History.
What price target have analysts set for SNOA?
2 analysts have issued twelve-month target prices for Sonoma Pharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Sonoma Pharmaceuticals' stock price to reach $8.50 in the next year. View Analyst Ratings for Sonoma Pharmaceuticals.
What are Wall Street analysts saying about Sonoma Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sonoma Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. " (4/25/2018)
- 2. Maxim Group analysts commented, "Sonoma reported strong sequential growth (F3Q18) with gross revenues of $4.8M driven by US and Latin America, up 46% versus the same period a year ago. US Dermatology was $2.2M up 78% versus last year. New products were a key driver of growth for the company. Net revenues were $2.9M, also showing strong growth at the prescribers level. The impact of 30 sales reps and five senior managers is manifesting as top line revenues. US revenues now represent more than 2/3 of all revenues with solid margins. The company closed the quarter with $8.6M in cash on the balance sheet." (2/8/2018)
Who are some of Sonoma Pharmaceuticals' key competitors?
Some companies that are related to Sonoma Pharmaceuticals include IntelGenx Technologies (IGXT), Zosano Pharma (ZSAN), OASMIA PHARMACE/ADR (OASM), AzurRx BioPharma (AZRX), Acerus Pharmaceuticals (TRLPF), Addex Pharmaceuticals (ADDXF), Moleculin Biotech (MBRX), Imprimis Pharmaceuticals (IMMY), Q BioMed (QBIO), Celsion (CLSN), Onconova Therapeutics (ONTX), Heat Biologics (HTBX), Evoke Pharma (EVOK), Capricor Therapeutics (CAPR) and Avenue Therapeutics (ATXI).
Who are Sonoma Pharmaceuticals' key executives?
Sonoma Pharmaceuticals' management team includes the folowing people:
- Mr. James Schutz, Pres, CEO & Director (Age 55)
- Mr. Robert E. Miller, CFO, COO & Corp. Sec. (Age 76)
- Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 54)
- Dr. Robert Northey Ph.D., Director of R&D (Age 61)
- Mr. Marc Umscheid, Chief Strategy & Marketing Officer
Has Sonoma Pharmaceuticals been receiving favorable news coverage?
Media coverage about SNOA stock has trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of 0.21 on Accern's scale. They also gave headlines about the company an impact score of 45.23 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Sonoma Pharmaceuticals' major shareholders?
Sonoma Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (1.46%). Company insiders that own Sonoma Pharmaceuticals stock include James J Schutz, Marc Umscheid and Robert E Miller. View Institutional Ownership Trends for Sonoma Pharmaceuticals.
Which major investors are buying Sonoma Pharmaceuticals stock?
SNOA stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Sonoma Pharmaceuticals stock in the last two years include James J Schutz, Marc Umscheid and Robert E Miller. View Insider Buying and Selling for Sonoma Pharmaceuticals.
How do I buy shares of Sonoma Pharmaceuticals?
Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sonoma Pharmaceuticals' stock price today?
One share of SNOA stock can currently be purchased for approximately $2.91.
How big of a company is Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals has a market capitalization of $13.80 million and generates $16.66 million in revenue each year. The company earns $-14,330,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. Sonoma Pharmaceuticals employs 243 workers across the globe.
How can I contact Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]
MarketBeat Community Rating for Sonoma Pharmaceuticals (SNOA)MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.